1. Please check and comment entries here.
Table of Contents

    Topic review

    Berberine in Oncogenic Herpesvirus Infections

    Subjects: Virology
    View times: 7
    Submitted by: Sherif T.S. Hassan


    Human herpesviruses are known to induce a broad spectrum of diseases, ranging from common cold sores to cancer, and infections with some types of these viruses, known as human oncogenic herpesviruses (HOHVs), can cause cancer. Challenges with viral latency, recurrent infections, and drug resistance have generated the need for finding new drugs with the ability to overcome these barriers. Berberine (BBR), a naturally occurring alkaloid, is known for its multiple biological activities, including antiviral and anticancer effects.

    1. Introduction

    Herpesviruses are a diverse group of large double-stranded DNA viruses that share a common virion morphology. Herpesviruses, which belong to the Herpesviridae family, are highly infectious and frequently infect humans for life and persist latently along with the ability to cause recurrent infections [1][2]. Some types of herpesvirus that can lead to cancer are recognized to be oncogenic, such as Epstein–Barr virus (EBV, also known as human herpesvirus 4) and Kaposi’s sarcoma-associated herpesvirus (KSHV, also known as human herpesvirus 8) [3][4]. On the other hand, some studies have reported other potentially human oncogenic herpesviruses (HOHVs) with an effect on various types of cancer such as herpes simplex virus 1 (HSV-1, also known as human herpesvirus 1), herpes simplex virus 2 (HSV-2, also known as human herpesvirus 2), and human cytomegalovirus (HCMV) [5][6][7]. It is known that herpesviruses use the infection strategy ‘‘run and hide,’’ and significant complications of these infections can be noticed once the immune system is compromised by various factors that negatively affect the immune system, including physiological and environmental factors [8][9]. Infections with herpesviruses are currently challenging to cure, and the clinical drugs used to treat them, such as acyclovir and other nucleoside analogs, do not entirely cure the disease or prevent recurrent infections while blocking the viral replication, thus reducing the duration of symptoms and promoting the healing of epithelial damage, lesions, and other cellular damages that were triggered by virus infection [10][11]. On the other hand, the overuse of these drugs has generated the problem of drug resistance, which in turn has adversely affected the treatment efficacy [12]. Currently, anti-herpesvirus drug development strategies face many challenges, and the most important tasks are linked with developing potent anti-herpesvirus medicines that can conquer the problems of drug resistance, viral latency, and recurrent infections and can also act with diverse mechanisms of action, minimum or no toxicity, and minimum adverse effects [13][14]. Most drug discovery strategies rely on natural products as a considerable source of new drug candidates with relatively safe profiles, especially from plant sources [15].
    Berberine (BBR), a secondary metabolite that is biosynthesized by various plant species and is commonly present in the roots, rhizomes, and stem barks of various Chinese herbs as well as several plants of the Berberis genus [16]. Chemically, this compound is a quaternary ammonium salt of an isoquinoline alkaloid (PubChem CID: 2353) with a molecular weight of 336.4 g/mol (Figure 1) [17]. Biologically, BBR in numerous preclinical and limited human studies has been proven to exert various beneficial bioactivities against several human diseases, including microbial infections, inflammation, various types of cancer, cardiovascular diseases, gastrointestinal disorders, neurodegenerative diseases, depression, and metabolic dysfunctions [16][18][19][20]. More information about berberine’s bioavailability and safety profile is discussed in a later section.
    Figure 1. Chemical structure of berberine.

    2. Berberine Targets Clinically Recognized Oncogenic Herpesviruses

    Herpesviruses are known to employ several immune evasion strategies to cause latent infections in their host cells with the ability to generate certain types of cancer [21]. The potential of developing cancer has been clinically confirmed with EBV and KSHV infections, which are classified as a class I carcinogen [22]. The major carcinogenic mechanisms employed by EBV and KSHV have recently been clarified, where both viruses can repress apoptosis and tumor suppressor pathways, enhance the oncogenic microenvironment, promote cellular migration, metastasis, and angiogenesis, and generate mutagenesis [3][21][22].
    This section records all studies concerning BBR and its protective effects on EBV and KSHV and their associated cancers, with a focus on the mechanisms of action and pathways along with effective concentrations or doses.

    2.1. Berberine Targets Epstein–Barr Virus and Its Associated Cancers

    EBV is a double-stranded DNA virus that belongs to the gamma-Herpesviridae subfamily [23] and was first identified in Burkitt’s lymphoma by Sir Anthony Epstein and colleagues in 1964 [24][25]. This pathogen was the first tumor virus discovered in humans and is principally linked with lymphomas and epithelial cell cancers [26]. Saliva exchange is the most known transmitting method for EBV infection and therefore symptomatic initial infection or infectious mononucleosis was described as ‘’kissing disease’’ [27]. There is a strong connection between EBV and the development of cancer, where experimental data confirmed that EBV infection is linked with various human proliferative diseases involving primarily epithelial or lymphoid cells, including nasopharyngeal carcinoma (NPC) [28][29]. EBV demonstrates a type II latency mechanism in NPC patients, and this latency is mainly characterized by the expression of Epstein–Barr nuclear antigen 1 (EBNA1), which was observed to be vital for the replication, partition, transcription, and protection of the viral genome [30][31][32]. Other critical latent membrane proteins and several non-coding RNAs are also expressed by the virus during the latency phase associated with NPC [33]. Therefore, such targets are very crucial in the design of new drug candidates useful in the management of EBV and its linked NPC [34].
    The direct suppression effect of BBR on EBV infection has been revealed in limited experiments, while its potent antitumor impacts have been explored in numerous in vitro and in vivo studies evaluated in multiple EBV positive-cancerous cells. For instance, in preclinical investigations (in vitro and in vivo), Wang and coauthors [35] showed the capacity of BBR to inhibit the latent and lytic replication of EBV-positive NPC cells and reduce cell proliferation, cause cell cycle arrest, and promote apoptosis in the EBV-positive NPC cells (Table 1). Their results unveiled diverse mechanisms of action at multiple molecular and cellular levels, suggesting BBR as a promising drug for the therapies of EBV infection and EBV-associated tumors such as NPC. In an in vivo experiment using athymic nude mice, BBR was observed to efficiently hinder the tumorigenicity and growth of EBV-positive NPC cells. The mechanism has been found to correlate with successful inhibition of signal transducer and activator of transcription 3 (STAT3) activation in NPC cells [36]. On the other hand, this study did not determine the inhibitory action of BBR against EBV. NPC could also be generated in the absence of EBV infection [37]. Since various drugs could work in a synergistic manner and provide enhanced treatment efficacy [38], BBR in combination with ginsenoside Rg3 (Rg3; an active molecule from Panax ginseng) was evaluated for improved anticancer properties and was detected to induce remarkable inhibition of NPC cell proliferation (in the absence of EBV infection) in vitro and in vivo. The underlying mechanism has been revealed to affect the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) signaling pathways [39]. In another research performed on EBV-transformed B cells and cancerous B cells, treatment with BBR led to significant induction of mitochondrial apoptosis, clarifying that the role of X-linked inhibitor of apoptosis protein-associated factor 1 (XAF1) as a supporter of the mitochondrial apoptosis pathway might offer a novel target for cancer therapy, mainly for cancers with wild-type p53 expression [40].
    Table 1. Protective effects of berberine against Epstein–Barr virus and its linked tumors.
    Type of Study, Assay, Virus, and Cells/Animals Outcomes Mechanism of Action Reference
    In vitro.
    Viral titer and Western blotting assays.
    EBV-positive NPC cells (HONE1 and HK1-EBV cells).
    At a concentration of 50 µM, BBR effectively reduced the production of virions in HONE1 and HK1-EBV cells, thus inhibiting latent and lytic replication of EBV in EBV-positive NPC cells. BBR decreased the expression of the EBV transcription factor BZLF1. [35]
    In vitro and in vivo.
    Various biochemical assays.
    EBV-positive NPC cells (HONE1 and HK1-EBV cells).
    NOD/SCID mice.
    At various concentrations in micromolar ranges, BBR successfully inhibited the viability of EBV-positive NPC cells and exposed cell cycle arrest and apoptosis in the EBV-positive NPC cells, providing a significant antitumor effect against NPC. Reduction of EBNA1 expression and inhibition of STAT3 activation. [35]
    In vivo.
    Tumorigenicity, Western blot, and immunohistochemistry analyses.
    EBV-positive NPC cells (C666-1) in athymic nude mice.
    Treatment with BBR at doses of 5 and 10 mg/kg significantly suppressed the tumorigenicity and growth of NPC cells. Inhibition of STAT3 activation.
    Inhibition of IL-6-activated STAT3.
    In vitro and in vivo.
    Cell proliferation, cell apoptosis, and Western blot assays.
    Xenograft tumor models of human NPC analysis.
    Male nude mice (BALB/C-NU).
    Combined treatment of BBR (10 mg/kg) with Rg3 (5 mg/kg) remarkably diminished tumor growth in NPC CNE2 xenograft nude mice. Enhancement of the expression of the apoptosis-associated protein Bax.
    Inhibition of survivin, PCNA, and anti-apoptotic protein Bcl-2 expressions via targeting the MAPK/ERK signaling pathways.
    In vitro.
    Multiple biochemical assays.
    EBV-transformed B cells and cancerous B cells.
    Treatment with BBR (50 µM) lessened cell viability and demonstrated apoptosis through a mitochondria-dependent pathway in EBV-transformed B cells and cancerous B cells. The mechanism has been elucidated through p53-mediated regulation of XAF1 and GADD45α expressions. [40]
    The displayed mechanisms have been revealed by in vitro and in vivo studies. BBR, berberine; EBNA1, Epstein–Barr nuclear antigen 1; EBV, Epstein–Barr virus; GADD45α, growth arrest and DNA damage inducible alpha; IL-6, interleukin-6; MAPK/ERK, mitogen-activated protein kinase/extracellular signal-regulated kinase; NOD/SCID, non-obese diabetic/severe combined immunodeficient; NPC, nasopharyngeal carcinoma; PCNA, proliferating cell nuclear antigen; Rg3, ginsenoside Rg3; STAT3, signal transducer and activator of transcription 3; XAF1, X-linked inhibitor of apoptosis protein-associated factor 1.

    2.2. Berberine Targets Kaposi’s Sarcoma-Associated Herpesvirus and Its Associated Cancers

    KSHV was first detected in Kaposi sarcoma (KS) and is associated with around 1% of all human malignancies. KSHV, a gamma-herpesvirus, is transmitted through sex and appears to be spread in other ways, such as through blood and saliva [41][42]. This virus is also linked with other malignancies such as primary effusion lymphoma (PEL) and a subset of multicentric Castleman’s disease (MCD). KS has been the focus of investigation in KSHV research, as it is the most common acquired immunodeficiency syndrome (AIDS)-related malignancy [43][44]. KS is a cancer that originates in lymph or blood vessels and commonly appears as lesions on the skin, the inside of the mouth, or internally. Genetic alterations driven by chromosomal instability represent the main feature of KSHV-associated cancers [45][46]. It has been proved that KSHV can infect several different cell types, including endothelial cells, B cells, epithelial cells, dendritic cells, monocytes, and fibroblasts, and the virus uses a specific strategy to attack the host cell, generating latent and lytic infection [47]. The viral life cycle of KSHV, and the mechanisms of inducing latency, have comprehensively been reviewed by Cesarman and colleagues [48], and we highly recommend the readers to refer to this work for more detailed information. BBR has been involved in extremely limited studies related to KSHV-associated malignancies research, and no antiviral experiments have been performed against KSHV so far.
    PEL, a blood cancer, is a large B-cell lymphoma located in the body cavities, described by pleural, peritoneal, and pericardial fluid lymphomatous effusions [49]. In a combined in vitro and in vivo study, Goto et al. [50] examined in depth the antitumor activity of BBR against PEL. Their work employed multiple in vitro biochemical assays, where BBR has successfully inhibited the proliferation of KSHV sequence-positive PEL (BC-1, BCBL-1, and TY-1) cells with 50% inhibitory concentration (IC50) values of 13.56, 29.17, and 32.82 µM, respectively. BBR also caused caspase-dependent apoptosis at concentrations of 30 and 100 µM. The mechanisms were found to relate to the ability of BBR to block nuclear factor κB (NF-κB) activation by impeding IκB kinase (IKK) phosphorylation, IκB phosphorylation, and IκB degradation, upstream targets of the NF-κB pathway, in PEL cells. Additionally, the authors used a xenograft mouse model to confirm the in vitro results, where treatment with BBR (at a dose of 10 mg/kg) significantly hindered the growth and invasion of PEL cells compared to untreated mice.
    Although we reviewed the promising role of BBR in preventing recurrent EBV infection and its connected cancers and KSHV-associated malignancies as well, additional in-depth studies that incorporate BBR into EBV and KSHV research are needed. Such studies should consider some facts that both viruses can control the host epigenetic machinery and contribute to the early phases of tumor development by initiating oncogenic changes within the cell, with the ability to hide using a strategy “hit and run’’ [51]. These facts make treatment of EBV and KSHV infections hard to efficiently manage. Therefore, we discuss in a later section various approaches to overwhelm these barriers.

    2.3. Berberine’s Mechanisms against γ-Herpesviruses and Their Linked Malignancies

    We have discussed above that in various in vitro and animal experiments, BBR has been shown to modulate the expression of a variety of genes and proteins and target several pathways involved in tumorigenesis connected with EBV and KSHV infections [35][36][39][40][50]. Moreover, we documented the capability of BBR to suppress EBV latent and lytic infection by affecting the expression of the transcription factor BZLF1, which is a critical factor required for viral replication [35]. Thus, in this section, we summarize these mechanisms and pathways in Figure 2, especially for readers who prefer to look at display items.
    Figure 2. Mechanisms of berberine against EBV replication (A) and EBV- and KSHV-associated cancers (B). The upward-pointing arrow indicates enhancement/upregulation, and the downward-pointing arrow indicates inhibition/downregulation. EBNA1, Epstein–Barr nuclear antigen 1; EBV, Epstein–Barr virus; GADD45α, growth arrest and DNA damage inducible alpha; IKK, IκB kinase; IL-6, interleukin-6; KSHV, Kaposi’s sarcoma-associated herpesvirus; MAPK/ERK, mitogen-activated protein kinase/extracellular signal-regulated kinase; NF-κB, nuclear factor kappa B; PCNA, proliferating cell nuclear antigen; STAT3, signal transducer and activator of transcription 3; XAF1, X-linked inhibitor of apoptosis protein-associated factor 1.

    3. Berberine between Inflammation and Cancer

    Herpesvirus infections are often tied with inflammation. This has been observed during the replication process of EBV and HCMV, where both viruses can trigger pro-inflammatory cytokine production and consequently could influence systemic inflammation [52][53]. Similarly, inflammation associated with post-infection complications of oral and genital herpes was reported in diverse medical observations [54][55][56]. Besides, KSHV inflammatory cytokine syndrome (KICS) caused by KSHV has recently been described [57][58].
    Inflammation is generated in complex pathways by microbial infections [59]. Once the body recognizes a pathogen attack, the innate immune system acts by producing pro-inflammatory cytokines as a part of a defense system to stop the pathogen and limit the replication process (in the case of viral infection). However, pro-inflammatory cytokines have a negative impact as they play a critical role in inflammatory diseases of infectious origin [60][61]. Modern research has disclosed that nearly 20% of human cancers are related to chronic inflammation caused by infections, where such inflammation can induce multiple DNA and cellular damages and lead to cancer [62][63].
    The promising therapeutic application of BBR as an anti-inflammatory agent has come to light in recent years and is documented in many investigations [64][65]. NF-κB and activator protein-1 (AP-1) signaling pathways and pro-inflammatory cytokines, such as interleukins (1, 1β, 6, 8, 10, and 12) and tumor necrosis factor-α (TNF-α), were detected to play critical functions in inflammation allied with HOHV infections [66][52]. The main mechanisms of BBR were found to be related to the inhibition of the NF-κB and AP-1 pathways and suppression of the expression of pro-inflammatory cytokines (Figure 3).
    Figure 3. Mechanisms by which berberine demonstrates anti-inflammatory properties against inflammation associated with human oncogenic herpesviruses. AP-1, activator protein-1; IL-1, interleukin-1; IL-1β, interleukin-1β; IL-6, interleukin-6; IL-8, interleukin-8; IL-10, interleukin-10; IL-12, interleukin-12; NF-κB, nuclear factor-kappa B; TNF-α, tumor necrosis factor-α.

    The entry is from 10.3390/v13061014


    1. Hassan, S.T.; Masarčíková, R.; Berchová, K. Bioactive natural products with anti-herpes simplex virus properties. J. Pharm. Pharmacol. 2015, 67, 1325–1336.
    2. Treml, J.; Gazdová, M.; Šmejkal, K.; Šudomová, M.; Kubatka, P.; Hassan, S.T.S. Natural Products-Derived Chemicals: Breaking Barriers to Novel Anti-HSV Drug Development. Viruses 2020, 12, 154.
    3. Manners, O.; Murphy, J.C.; Coleman, A.; Hughes, D.J.; Whitehouse, A. Contribution of the KSHV and EBV lytic cycles to tumourigenesis. Curr. Opin. Virol. 2018, 32, 60–70.
    4. Dittmer, D.P.; Damania, B.; Sin, S.H. Animal models of tumorigenic herpesviruses--An update. Curr. Opin. Virol. 2015, 14, 145–150.
    5. Wołącewicz, M.; Becht, R.; Grywalska, E.; Niedźwiedzka-Rystwej, P. Herpesviruses in Head and Neck Cancers. Viruses 2020, 12, 172.
    6. Tomkins, A.; White, C.; Higgins, S.P. Primary herpes simplex virus infection mimicking cervical cancer. BMJ Case Rep. 2015, 2015, bcr2015210194.
    7. Herbein, G. The Human Cytomegalovirus, from Oncomodulation to Oncogenesis. Viruses 2018, 10, 408.
    8. Glaunsinger, B.A. Modulation of the Translational Landscape During Herpesvirus Infection. Annu. Rev. Virol. 2015, 2, 311–333.
    9. Asha, K.; Sharma-Walia, N. Targeting Host Cellular Factors as a Strategy of Therapeutic Intervention for Herpesvirus Infections. Front. Cell Infect. Microbiol. 2021, 11, 603309.
    10. Poole, C.L.; James, S.H. Antiviral Therapies for Herpesviruses: Current Agents and New Directions. Clin. Ther. 2018, 40, 1282–1298.
    11. Hassan, S.T.S. Brassicasterol with Dual Anti-Infective Properties against HSV-1 and Mycobacterium tuberculosis, and Cardiovascular Protective Effect: Nonclinical In Vitro and In Silico Assessments. Biomedicines 2020, 8, 132.
    12. Brezáni, V.; Leláková, V.; Hassan, S.T.S.; Berchová-Bímová, K.; Nový, P.; Klouček, P.; Maršík, P.; Dall’Acqua, S.; Hošek, J.; Šmejkal, K. Anti-Infectivity against Herpes Simplex Virus and Selected Microbes and Anti-Inflammatory Activities of Compounds Isolated from Eucalyptus globulus Labill. Viruses 2018, 10, 360.
    13. Hassan, S.T.S.; Šudomová, M.; Berchová-Bímová, K.; Šmejkal, K.; Echeverría, J. Psoromic Acid, a Lichen-Derived Molecule, Inhibits the Replication of HSV-1 and HSV-2, and Inactivates HSV-1 DNA Polymerase: Shedding Light on Antiherpetic Properties. Molecules 2019, 24, 2912.
    14. Čulenová, M.; Sychrová, A.; Hassan, S.T.S.; Berchová-Bímová, K.; Svobodová, P.; Helclová, A.; Michnová, H.; Hošek, J.; Vasilev, H.; Suchý, P.; et al. Multiple In vitro biological effects of phenolic compounds from Morus alba root bark. J. Ethnopharmacol. 2020, 248, 112296.
    15. Hassan, S.T.S.; Švajdlenka, E. Biological Evaluation and Molecular Docking of Protocatechuic Acid from Hibiscus sabdariffa L. as a Potent Urease Inhibitor by an ESI-MS Based Method. Molecules 2017, 22, 1696.
    16. Feng, X.; Sureda, A.; Jafari, S.; Memariani, Z.; Tewari, D.; Annunziata, G.; Barrea, L.; Hassan, S.T.S.; Šmejkal, K.; Malaník, M.; et al. Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics. Theranostics 2019, 9, 1923–1951.
    17. Wang, K.; Feng, X.; Chai, L.; Cao, S.; Qiu, F. The metabolism of berberine and its contribution to the pharmacological effects. Drug Metab. Rev. 2017, 49, 139–157.
    18. Warowicka, A.; Nawrot, R.; Goździcka-Józefiak, A. Antiviral activity of berberine. Arch. Virol. 2020, 165, 1935–1945.
    19. Zeng, Q.; Deng, H.; Li, Y.; Fan, T.; Liu, Y.; Tang, S.; Wei, W.; Liu, X.; Guo, X.; Jiang, J.; et al. Berberine Directly Targets the NEK7 Protein to Block the NEK7-NLRP3 Interaction and Exert Anti-inflammatory Activity. J. Med. Chem. 2021, 64, 768–781.
    20. Liu, D.; Meng, X.; Wu, D.; Qiu, Z.; Luo, H. A Natural Isoquinoline Alkaloid with Antitumor Activity: Studies of the Biological Activities of Berberine. Front. Pharmacol. 2019, 10, 9.
    21. Münz, C. Latency and lytic replication in Epstein-Barr virus-associated oncogenesis. Nat. Rev. Microbiol. 2019, 17, 691–700.
    22. Charostad, J.; Nakhaie, M.; Dehghani, A.; Faghihloo, E. The interplay between EBV and KSHV viral products and NF-κB pathway in oncogenesis. Infect. Agents Cancer. 2020, 15, 62.
    23. Young, L.S.; Yap, L.F.; Murray, P.G. Epstein-Barr virus: More than 50 years old and still providing surprises. Nat. Rev. Cancer 2016, 16, 789–802.
    24. Epstein, M.A.; Achong, B.G.; Barr, Y.M. Virus particles in cultured lymphoblasts from Burkitt’s lymphoma. Lancet 1964, 1, 702–703.
    25. Epstein, M.A.; Henle, G.; Achong, B.G.; Barr, Y.M. Morphological and biological studies on a virus in cultured lymphoblasts from Burkitt’s lymphoma. J. Exp. Med. 1964, 121, 761–770.
    26. Farrell, P.J. Epstein–Barr virus and cancer. Annu. Rev. Pathol. 2019, 14, 29–53.
    27. Ciccarese, G.; Trave, I.; Herzum, A.; Parodi, A.; Drago, F. Dermatological manifestations of Epstein-Barr virus systemic infection: A case report and literature review. Int. J. Dermatol. 2020, 59, 1202–1209.
    28. Cui, Q.; Feng, F.T.; Xu, M.; Liu, W.S.; Yao, Y.Y.; Xie, S.H.; Li, X.Z.; Ye, Z.L.; Feng, Q.S.; Chen, L.Z.; et al. Nasopharyngeal carcinoma risk prediction via salivary detection of host and Epstein-Barr virus genetic variants. Oncotarget 2016, 8, 95066–95074.
    29. Xu, M.; Cheung, C.C.; Chow, C.; Lun, S.W.; Cheung, S.T.; Lo, K.W. Overexpression of PIN1 enhances cancer growth and aggressiveness with cyclin D1 induction in EBV-associated nasopharyngeal carcinoma. PLoS ONE. 2016, 11, e0156833.
    30. Wang, F.W.; Wu, X.R.; Liu, W.J.; Liang, Y.J.; Huang, Y.F.; Liao, Y.J.; Shao, C.K.; Zong, Y.S.; Mai, S.J.; Xie, D. The nucleotide polymorphisms within the Epstein-Barr virus C and Q promoters from nasopharyngeal carcinoma affect transcriptional activity in vitro. Eur. Arch. Otorhinolaryngol. 2012, 269, 931–938.
    31. Shen, Y.; Zhang, S.; Sun, R.; Wu, T.; Qian, J. Understanding the interplay between host immunity and Epstein-Barr virus in NPC patients. Emerg. Microbes Infect. 2015, 4, 20.
    32. Kelly, G.L.; Stylianou, J.; Rasaiyaah, J.; Wei, W.; Thomas, W.; Croom-Carter, D.; Kohler, C.; Spang, R.; Woodman, C.; Kellam, P.; et al. Different patterns of Epstein-Barr virus latency in endemic Burkitt lymphoma (BL) lead to distinct variants within the BL-associated gene expression signature. J. Virol. 2013, 87, 2882–2894.
    33. Kempkes, B.; Ling, P.D. EBNA2 and Its Coactivator EBNA-LP. Curr. Top. Microbiol. Immunol. 2015, 391, 35–59.
    34. Frappier, L. Contributions of Epstein-Barr nuclear antigen 1 (EBNA1) to cell immortalization and survival. Viruses 2012, 4, 1537–1547.
    35. Wang, C.; Wang, H.; Zhang, Y.; Guo, W.; Long, C.; Wang, J.; Liu, L.; Sun, X. Berberine inhibits the proliferation of human nasopharyngeal carcinoma cells via an Epstein-Barr virus nuclear antigen 1-dependent mechanism. Oncol. Rep. 2017, 37, 2109–2120.
    36. Tsang, C.M.; Cheung, Y.C.; Lui, V.W.; Yip, Y.L.; Zhang, G.; Lin, V.W.; Cheung, K.C.; Feng, Y.; Tsao, S.W. Berberine suppresses tumorigenicity and growth of nasopharyngeal carcinoma cells by inhibiting STAT3 activation induced by tumor associated fibroblasts. BMC Cancer 2013, 13, 619.
    37. Tao, D.; Zhang, N.; Huang, Q.; Ge, C.; Li, Q.; Li, S.; Weng, K.; Guo, Q.; Sui, J.; Wang, C.; et al. Association of Epstein-Barr virus infection with peripheral immune parameters and clinical outcome in advanced nasopharyngeal carcinoma. Sci. Rep. 2020, 10, 21976.
    38. Hassan, S.T.S.; Berchová-Bímová, K.; Petráš, J.; Hassan, K.T.S. Cucurbitacin B interacts synergistically with antibiotics against Staphylococcus aureus clinical isolates and exhibits antiviral activity against HSV-1. S. Afr. J. Bot. 2017, 108, 90–94.
    39. Zhou, F.; Hu, J.; Dai, N.; Song, L.; Lin, T.; Liu, J.; Li, K.; Peng, Z.; He, Y.; Liao, D.-F. Berberine and ginsenoside Rg3 act synergistically via the MAPK/ERK pathway in nasopharyngeal carcinoma cells. J. Funct. Foods 2020, 66, 103802.
    40. Park, G.B.; Park, S.H.; Kim, D.; Kim, Y.S.; Yoon, S.H.; Hur, D.Y. Berberine induces mitochondrial apoptosis of EBV-transformed B cells through p53-mediated regulation of XAF1 and GADD45α. Int. J. Oncol. 2016, 49, 411–421.
    41. Kumar, B.; Roy, A.; Veettil, M.V.; Chandran, B. Insight into the Roles of E3 Ubiquitin Ligase c-Cbl, ESCRT Machinery, and Host Cell Signaling in Kaposi’s Sarcoma-Associated Herpesvirus Entry and Trafficking. J. Virol. 2018, 92.
    42. Minhas, V.; Wood, C. Epidemiology and transmission of Kaposi’s sarcoma-associated herpesvirus. Viruses 2014, 6, 4178–4194.
    43. Ueda, K. KSHV Genome Replication and Maintenance in Latency. Adv. Exp. Med. Biol. 2018, 1045, 299–320.
    44. Li, S.; Bai, L.; Dong, J.; Sun, R.; Lan, K. Kaposi’s Sarcoma-Associated Herpesvirus: Epidemiology and Molecular Biology. Adv. Exp. Med. Biol. 2017, 1018, 91–127.
    45. Schneider, J.W.; Dittmer, D.P. Diagnosis and Treatment of Kaposi Sarcoma. Am. J. Clin. Dermatol. 2017, 18, 529–539.
    46. Watanabe, T.; Sugimoto, A.; Hosokawa, K.; Fujimuro, M. Signal Transduction Pathways Associated with KSHV-Related Tumors. Adv. Exp. Med. Biol. 2018, 1045, 321–355.
    47. Abere, B.; Mamo, T.M.; Hartmann, S.; Samarina, N.; Hage, E.; Rückert, J.; Hotop, S.K.; Büsche, G.; Schulz, T.F. The Kaposi’s sarcoma-associated herpesvirus (KSHV) non-structural membrane protein K15 is required for viral lytic replication and may represent a therapeutic target. PLoS Pathog. 2017, 13, e1006639.
    48. Cesarman, E.; Damania, B.; Krown, S.E.; Martin, J.; Bower, M.; Whitby, D. Kaposi sarcoma. Nat. Rev. Dis. Primers 2019, 5, 9.
    49. Shimada, K.; Hayakawa, F.; Kiyoi, H. Biology and management of primary effusion lymphoma. Blood 2018, 132, 1879–1888.
    50. Goto, H.; Kariya, R.; Shimamoto, M.; Kudo, E.; Taura, M.; Katano, H.; Okada, S. Antitumor effect of berberine against primary effusion lymphoma via inhibition of NF-κB pathway. Cancer Sci. 2012, 103, 775–781.
    51. Damania, B.; Münz, C. Immunodeficiencies that predispose to pathologies by human oncogenic γ-herpesViruses. FEMS Microbiol. Rev. 2019, 43, 181–192.
    52. Bennett, J.M.; Glaser, R.; Malarkey, W.B.; Beversdorf, D.Q.; Peng, J.; Kiecolt-Glaser, J.K. Inflammation and reactivation of latent herpesviruses in older adults. Brain Behav. Immun. 2012, 26, 739–746.
    53. Cruz-Muñoz, M.E.; Fuentes-Pananá, E.M. Beta and Gamma Human Herpesviruses: Agonistic and Antagonistic Interactions with the Host Immune System. Front Microbiol. 2018, 8, 2521.
    54. Lobo, A.M.; Agelidis, A.M.; Shukla, D. Pathogenesis of herpes simplex keratitis: The host cell response and ocular surface sequelae to infection and inflammation. Ocul. Surf. 2019, 17, 40–49.
    55. Islam, S.M.S.; Sohn, S. HSV-Induced Systemic Inflammation as an Animal Model for Behçet’s Disease and Therapeutic Applications. Viruses 2018, 10, 511.
    56. Johnston, C.; Corey, L. Current Concepts for Genital Herpes Simplex Virus Infection: Diagnostics and Pathogenesis of Genital Tract Shedding. Clin. Microbiol. Rev. 2016, 29, 149–161.
    57. Alomari, N.; Totonchy, J. Cytokine-Targeted Therapeutics for KSHV-Associated Disease. Viruses 2020, 12, 1097.
    58. Polizzotto, M.N.; Uldrick, T.S.; Wyvill, K.M.; Aleman, K.; Marshall, V.; Wang, V.; Whitby, D.; Pittaluga, S.; Jaffe, E.S.; Millo, C.; et al. Clinical Features and Outcomes of Patients with Symptomatic Kaposi Sarcoma Herpesvirus (KSHV)-associated Inflammation: Prospective Characterization of KSHV Inflammatory Cytokine Syndrome (KICS). Clin. Infect. Dis. 2016, 62, 730–738.
    59. Shrivastava, G.; León-Juárez, M.; García-Cordero, J.; Meza-Sánchez, D.E.; Cedillo-Barrón, L. Inflammasomes and its importance in viral infections. Immunol. Res. 2016, 64, 1101–1117.
    60. Liu, T.; Zhang, L.; Joo, D.; Sun, S.C. NF-κB signaling in inflammation. Signal Transduct. Target. Ther. 2017, 2, 17023.
    61. Carty, M.; Guy, C.; Bowie, A.G. Detection of viral infections by innate immunity. Biochem. Pharmacol. 2020, 183, 114316.
    62. Crusz, S.M.; Balkwill, F.R. Inflammation and cancer: Advance and new agents. Nat. Rev. Clin. Oncol. 2015, 12, 584–596.
    63. Murata, M. Inflammation and cancer. Environ. Health Prev. Med. 2018, 23, 50.
    64. Zou, K.; Li, Z.; Zhang, Y.; Zhang, H.Y.; Li, B.; Zhu, W.L.; Shi, J.Y.; Jia, Q.; Li, Y.M. Advances in the study of berberine and its derivatives: A focus on anti-inflammatory and anti-tumor effects in the digestive system. Acta Pharmacol. Sin. 2017, 38, 157–167.
    65. Ehteshamfar, S.M.; Akhbari, M.; Afshari, J.T.; Seyedi, M.; Nikfar, B.; Shapouri-Moghaddam, A.; Ghanbarzadeh, E.; Momtazi-Borojeni, A.A. Anti-inflammatory and immune-modulatory impacts of berberine on activation of autoreactive T cells in autoimmune inflammation. J. Cell. Mol. Med. 2020, 24, 13573–13588.
    66. Šudomová, M.; Hassan, S.T.S. Nutraceutical Curcumin with Promising Protection against Herpesvirus Infections and Their Associated Inflammation: Mechanisms and Pathways. Microorganisms 2021, 9, 292.